文献速递免疫规划

ChAdOx1 nCoV-19(AZD1222)疫苗在6-17岁儿童中的安全性与免疫原性:2期单盲随机对照试验(COV006)最终结果

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
PubMed 文献 · Vaccine · 2025-08-25

这项在英国四中心开展的2期单盲随机对照试验纳入261名6-17岁儿童和青少年,比较两剂ChAdOx1 nCoV-19与Bexsero疫苗的安全性(主要结局)和免疫原性(次要结局)。随访12个月最终结果显示,未报告疫苗相关严重不良事件,两剂方案在试验人群中具有免疫原性和安全性,未发生突破感染者免疫反应持续至12个月。

要点

  • 报告5例严重不良事件和4例特殊关注不良事件,均与试验疫苗无关,无死亡。
  • 6-11岁组抗刺突(Wuhan)ELISA几何平均滴度从基线1 EU/ml升至D364的796 EU(95%CI 161-3948,n=4)。
  • 12-17岁组112天间隔两剂方案D364几何平均滴度为1432 EU/ml(95%CI 2337-6083,n=6)。

核心结论

  • 两剂ChAdOx1 nCoV-19方案在试验人群中具有免疫原性和安全性,未报告疫苗相关严重不良事件。
  • 未发生突破感染的参与者免疫反应持续至12个月。

研究设计与样本

  • 在英国四个中心开展的单盲、随机对照试验,招募261名6-17岁儿童和青少年。
  • 参与者接受两剂ChAdOx1 nCoV-19或Bexsero疫苗(对照)。
  • 主要结局为安全性(接种后28天内不良事件及全程严重不良事件),次要结局为免疫原性(SARS-CoV-2抗刺突ELISA和ELISpot)。

主要发现

  • 报告5例严重不良事件和4例特殊关注不良事件,均与试验疫苗接种无关,无死亡。
  • 6-11岁组抗刺突(Wuhan)ELISA几何平均滴度基线为1 EU/ml(95%CI 1-2),D364为796 EU(95%CI 161-3948,n=4)。
  • 12-17岁组112天间隔两剂方案几何平均滴度基线为1 EU/ml(95%CI 1-2,n=3),D364为1432 EU/ml(95%CI 2337-6083,n=6)。
  • 12-17岁组28天间隔两剂方案几何平均滴度基线为3 EU/ml(95%CI 0-62),D364为392 EU/ml(95%CI 24, 6493,n=3)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paediatric COVID-19 vaccination programmes were initiated in response to the coronavirus pandemic declared by the World Health Organisation (WHO) in 2020. Ten COVID-19 vaccines received WHO Emergency Use Listing, however, only five were approved for use in children. ChAdOx1 nCoV-19 (AZD1222) was approved in adults in a two-dose regimen. We previously reported interim findings of a phase 2 study of ChAdOx1 nCoV-19 in children with immunogenicity, comparable with adults. Final results after 12 month follow-up are reported. METHODS: Single-blind, randomised controlled trial across four UK centres, recruiting 261 children and adolescents (aged 6-17 years). Participants received either two doses of ChAdOx1 nCoV-19 or Bexsero vaccine (controls). The primary outcome was safety (adverse events for 28 days following vaccination and serious adverse events throughout), and secondary outcome was immunogenicity (measured by SARS-CoV-2 anti-spike enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunosorbent spot (ELISpot)). FINDINGS: Five serious adverse events and four adverse events of special interest were reported. None were related to study vaccinations, and there were no deaths. Geometric mean titres (GMTs) from an anti-spike (Wuhan) ELISA in participants aged 6-11 years were 1 EU/ml (95% CI 1-2) at baseline versus 796 EU (95% CI 161-3948, n =4) at D364. In participants aged 12-17 years, GMTs were 1 EU/ml (95% CI 1-2, n=3) at baseline versus 1432 EU/ml (95% CI 2337-6083; n=6) at D364 (2 dose regimen at 112-day interval), compared to 3 EU/ml (95% CI 0-62) at baseline versus 392 EU/ml (95% CI 24, 6493; n=3) at D364 (2 dose regimen at a 28-day interval). INTERPRETATION: A two-dose regimen of ChAdOx1 nCoV-19 was immunogenic and safe in the trial population. No vaccine-related serious adverse events were reported. Immune responses persisted to 12 months in participants who did not experience breakthrough infection, This trial was registered with ISRCTN, trial number 15638344. FUNDING: The study was funded by the Department of Health and Social Care, through the National Institute for Health Research, and AstraZeneca.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Li G, Marchevsky NG, Macaulay G, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006). Vaccine. 2025. PMID: 40857840. doi:10.1016/j.vaccine.2025.127597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。